<DOC>
	<DOCNO>NCT00859651</DOCNO>
	<brief_summary>This phase II study enroll 20 postmenopausal woman high risk breast cancer development . The goal determine whether one-year intervention high-dose vitamin D 2 different dos ( 20,000 IU weekly 30,000 IU weekly ) increase circulate blood level vitamin D obtain preliminary data biologic effect vitamin D breast cancer prevention .</brief_summary>
	<brief_title>Vitamin D Postmenopausal Women High Risk Breast Cancer</brief_title>
	<detailed_description>Participants receive oral vitamin D3 , cholecalciferol 20,000 IU 30,000 IU weekly . Before begin intervention , participant general physical exam include clinical breast exam anthropometric measure , morning blood draw ( analysis 25 ( OH ) D , 1,25 ( OH ) D , PTH , IGF-I , IGFBP-3 , estradiol , estrone , testosterone , SHBG baseline , 6 month , 12 month ) bilateral mammogram ( baseline 12 month ) . Participants also complete baseline questionnaire , collect data demographic information breast cancer risk factor . In addition , collect data vitamin D source diet sunlight exposure use validated questionnaire administer baseline 12 month . For follow-up visit , participant see study site month 3 , 6 , 9 , 12 . During visit , drug dispense , adherence ascertain , adverse event also assess . In addition , blood ( serum calcium , albumin , creatinine ) urine ( urine calcium , creatinine ) collect monitor toxicity . A 24-hour urine collection conduct baseline 12 month assess hypercalciuria . After 1 year intervention , participant complete physical exam include clinical breast exam , bilateral mammogram , blood draw , complete follow-up questionnaire .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Elevated risk breast cancer define least one following : ( 1 ) Predicted 5year modified Gail model risk 1.67 % great , ( 2 ) Lobular carcinoma situ , ( 3 ) Known BRCA1 BRCA2 deleterious mutation carrier , ( 4 ) Prior history ductal carcinoma situ , current tamoxifen use prior radiation contralateral breast . Age 21 year old . Postmenopausal define &gt; 6 month since last menstrual period , prior bilateral oophrectomy , serum FSH/LH value consistent institutional normal value postmenopausal state . Baseline mammographic density â‰¥25 % assess qualitatively mammographer ( 2550 % = `` scattered fibroglandular density '' ; &gt; 5075 % = `` heterogeneously dense breast '' ; &gt; 75 % = `` extremely dense breast '' ) . Baseline serum 25hydroxyvitamin D &lt; 32 ng/ml . Normal breast exam mammogram ( BIRADS score 1 2 ) abnormal breast image benign breast biopsy without evidence cancer . Normal baseline breast MRI ( BIRADS score 1 , 2 , 3 ) . Prior tamoxifen raloxifene use allow provided treatment discontinue least 28 day prior enrollment . At least one breast available imaging . No bilateral breast implant . Willingness take vitamin D supplement one year intervention , 1000mg calcium supplementation allow . Normal serum calcium . Adequate renal hepatic function : serum creatinine , bilirubin , AST , ALT alkaline phosphatase &lt; 2.0 x institutional upper limit normal ( IULN ) . Zubrod performance status 0 1 . Other prior malignancy . The following allowed : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer participant currently complete remission , cancer ( include breast cancer ) participant diseasefree 5 year . History kidney stone . Hypersensitivity reactions vitamin D. On estrogen replacement therapy . Significant medical psychiatric condition would preclude study completion .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>breast cancer chemoprevention</keyword>
	<keyword>vitamin D</keyword>
	<keyword>breast density</keyword>
</DOC>